导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 19.44% | 425/4773 |
| 近一周 | 0.12% | 797/5465 |
| 近一月 | -5.53% | 3789/5421 |
| 近一季 | -13.20% | 4113/5231 |
| 近半年 | 18.41% | 267/4920 |
| 近一年 | 24.69% | 334/4394 |
| 近两年 | 140.35% | 309/2954 |
| 近三年 | 89.49% | 206/2253 |
| 成立以来 | 112.39% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.63% 3324/4961 |
59.25% 419/5312 |
- - |
- - |
| 2025 | 55.88% 313/4813 |
2.58% 1323/3635 |
3.23% 1097/4076 |
48.24% 385/4524 |
-0.70% 2602/4813 |
| 2024 | 10.49% 1406/3463 |
-3.16% 1475/2808 |
-5.00% 1615/3014 |
21.35% 592/3129 |
-1.03% 1568/3463 |
| 2023 | -22.97% 1945/2656 |
0.77% 1700/2280 |
-7.62% 1874/2385 |
-9.94% 1911/2515 |
-8.12% 2250/2655 |
| 2022 | -30.26% 1626/2207 |
-17.76% 1257/1919 |
8.86% 321/2016 |
-21.16% 1895/2113 |
-1.18% 1682/2208 |
| 2021 | 6.73% 510/1822 |
-5.37% 918/1255 |
20.43% 144/1330 |
-6.42% 926/1466 |
0.07% 1171/1822 |
| 2020 | 75.14% 56/1250 |
4.84% 59/1028 |
28.85% 89/1067 |
10.19% 575/1164 |
17.66% 114/1184 |
| 2019 | - - |
- - |
- - |
8.15% 68/850 |
10.63% 113/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 华夏战略新兴成指ETF联接A VS. 长安沪深300非周期A(740101) |